K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 125 JPY
Market Cap: 156.2B JPY

Relative Value

The Relative Value of one Kaken Pharmaceutical Co Ltd stock under the Base Case scenario is hidden JPY. Compared to the current market price of 4 125 JPY, Kaken Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Kaken Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
28
vs Industry
53
Median 3Y
1.8
Median 5Y
1.9
Industry
2.6
Forward
1.8
vs History
0
vs Industry
40
Median 3Y
16.9
Median 5Y
15
Industry
21.7
Forward
48.8
vs History
vs Industry
45
Median 3Y
10
Median 5Y
10.7
Industry
16.7
vs History
vs Industry
32
Median 3Y
12.5
Median 5Y
13.7
Industry
23.1
vs History
31
vs Industry
58
Median 3Y
1
Median 5Y
1
Industry
2.2
vs History
6
vs Industry
70
Median 3Y
1
Median 5Y
1
Industry
2.9
Forward
1.2
vs History
7
vs Industry
74
Median 3Y
1.7
Median 5Y
1.8
Industry
5.5
vs History
0
vs Industry
49
Median 3Y
5.8
Median 5Y
4.5
Industry
13.2
Forward
14.2
vs History
0
vs Industry
47
Median 3Y
7.6
Median 5Y
5.1
Industry
16.8
vs History
vs Industry
50
Median 3Y
5.1
Median 5Y
5.4
Industry
15.9
vs History
vs Industry
38
Median 3Y
6.3
Median 5Y
7.1
Industry
19.2
vs History
28
vs Industry
60
Median 3Y
0.8
Median 5Y
0.8
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Kaken Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Kaken Pharmaceutical Co Ltd
TSE:4521
156.2B JPY 1.9 240 23.5 62.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.7 159.1
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.3B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average P/E: 48.3
240
-54%
N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average EV/EBITDA: 401.8
23.5
-42%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Average EV/EBIT: 1 717.4
62.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3